AXSOME THERAPEUTICS, INC.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$196M
↑+65.0% +$77Mvs FY2024 (Q4)
Gross Profit
$184M
↑+69.7% +$75Mvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $196M | $119M |
| COGS | $12M | $11M |
| Gross Profit | $184M | $108M |
| R&D | $49M | $55M |
| SG&A | $169M | $113M |
| D&A | $114K | $129K |
| Other OpEx | $0 | $0 |
| Operating Income | $0 | $0 |
| Interest Exp. | $0 | $0 |
| Other Non-Op | $0 | $0 |
| Pretax Income | $0 | $0 |
| Tax | $0 | $0 |
| Net Income | $0 | $0 |
QuarterCharts · SEC EDGAR data · AXSM · Comparing FY2025 (Q4) vs FY2024 (Q4)